ResMed Inc. Chairman and CEO Michael J. Farrell filed a Form 4 on August 10, 2026, reporting a stock option exercise and same-day share sale that occurred on August 7, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Farrell exercised 4,991 ResMed Common Stock options at an exercise price of $146.34 per share on August 7, 2026.
- Shares sold: 4,991 shares of ResMed Common Stock were disposed of at a weighted average sale price of $205.6895, with individual trades ranging from $202.410 to $204.160.
- Post-transaction direct ownership: Farrell directly beneficially owns 466,256 shares of ResMed Common Stock following the reported transactions.
- Indirect ownership: An additional 2,090 shares are held indirectly through the Lisette and Michael Farrell Family Trust.
- Remaining options: 14,975 ResMed Common Stock options remain directly held, with an expiration date of November 21, 2026.
- 10b5-1 plan: The transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024.
ResMed CEO Farrell Exercises Options and Sells Shares Under Pre-Set Trading Plan
According to the filing, Michael J. Farrell, Chairman and CEO of ResMed Inc. (NYSE:RMD), executed two linked transactions on August 7, 2026. First, Farrell exercised 4,991 stock options at a conversion price of $146.34 per share, using transaction code "M," which acquired 4,991 shares and brought his direct beneficial ownership to 471,247 shares.
In the same-day sale, coded "S," Farrell disposed of 4,991 shares at a weighted average price of $205.6895. The filing notes that "this transaction was executed in multiple trades at prices ranging from $202.410 - $204.160" and that the reported price reflects the weighted average. Following the sale, his direct beneficial ownership stood at 466,256 shares. Both transactions were carried out under a Rule 10b5-1 plan that Farrell adopted on October 31, 2024, according to the filing.
The filing also discloses that the exercised options were part of a grant that first became exercisable on November 11, 2020, and vest at one-third per year, with an expiration date of November 21, 2026. After the exercise, 14,975 options remain directly held by Farrell. In addition to his direct holdings, the filing indicates that 2,090 shares are held indirectly through the Lisette and Michael Farrell Family Trust.
What Was Disclosed
The filing reports a same-day option exercise and sale of 4,991 ResMed shares by Chairman and CEO Michael J. Farrell on August 7, 2026, conducted under a pre-established 10b5-1 plan, leaving him with 466,256 directly held shares and 14,975 remaining options.



Please wait processing your request...